Spark Therapeutics enters into definitive merger agreement with Roche

Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion. Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group Transaction expected to close in Q2, 2019.

Read more at the company website.

ARCHIVE
SEARCH BY TAGS
FOLLOW US
4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2020 by 4BIO Ventures Management Ltd